Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.

Fernandez-Rodriguez, Laura; Cianciaruso, Chiara; Bill, Ruben; Trefny, Marcel P; Klar, Richard; Kirchhammer, Nicole; Buchi, Mélanie; Festag, Julia; Michel, Sven; Kohler, Rainer H; Jones, Elham; Maaske, Andre; Kashyap, Abhishek S; Jaschinski, Frank; Dixon, Karen O; Pittet, Mikael J; Zippelius, Alfred (2023). Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity. Journal for immunotherapy of cancer, 11(5) BioMed Central 10.1136/jitc-2023-006714

Preview

Text e006714.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (7MB) | Preview

BACKGROUND

Although immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing network linking innate and adaptive immunity. Here, we present an antisense oligonucleotide (ASO)-based strategy that dually targets toll-like receptor 9 (TLR9) and programmed cell death ligand 1 (PD-L1), aiming to overcome resistance to anti-PD-L1 monoclonal therapy.

METHODS

We designed a high-affinity immunomodulatory IM-TLR9:PD-L1-ASO antisense oligonucleotide (hereafter, IM-T9P1-ASO) targeting mouse PD-L1 messenger RNA and activating TLR9. Then, we performed in vitro and in vivo studies to validate the IM-T9P1-ASO activity, efficacy, and biological effects in tumors and draining lymph nodes. We also performed intravital imaging to study IM-T9P1-ASO pharmacokinetics in the tumor.

RESULTS

IM-T9P1-ASO therapy, unlike PD-L1 antibody therapy, results in durable antitumor responses in multiple mouse cancer models. Mechanistically, IM-T9P1-ASO activates a state of tumor-associated dendritic cells (DCs), referred to here as DC3s, which have potent antitumor potential but express the PD-L1 checkpoint. IM-T9P1-ASO has two roles: it triggers the expansion of DC3s by engaging with TLR9 and downregulates PD-L1, thereby unleashing the antitumor functions of DC3s. This dual action leads to tumor rejection by T cells. The antitumor efficacy of IM-T9P1-ASO depends on the antitumor cytokine interleukin-12 (IL-12), produced by DC3s, and Batf3, a transcription factor required for DC development.

CONCLUSIONS

By simultaneously targeting TLR9 and PD-L1, IM-T9P1-ASO amplifies antitumor responses via DC activation, leading to sustained therapeutic efficacy in mice. By highlighting differences and similarities between mouse and human DCs, this study could serve to develop similar therapeutic strategies for patients with cancer.

Interest & Impact

Downloads

15 since deposited on 29 Nov 2023
15 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item